Showing: 1 - 5 of 5 RESULTS

UVDI Announces UV-C Device Presentations at the 16th World Congress on Public Health 2020

Ultraviolet Devices, Inc. (UVDI), a global leader in UV-C surface disinfecting and indoor air quality products, today announced its first Italian hospital studies demonstrating the advanced effectiveness of the UVDI-360 Room Sanitizer will be presented at the 16th World Congress on Public Health 2020, taking place October 12 – 16, 2020. The novel research, conducted by Dr. Gabriele Messina, Associate Professor of Public Health, University of Siena, at the Rugani Hospital Monteriggioni in Siena, demonstrates the UVDI-360’s ability to inactivate pathogens in the hospital environment as part of varied cleaning protocols, in multiple high-risk locations and at different disinfecting cycle times.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201011005076/en/

Researchers from the University of Siena will present “Six ultraviolet minutes for cleaner operating theatres” at the 16th World Congress on Public Health 2020. (Photo: Business Wire)

Presentations from Dr. Messina and his Team at the University of Siena include:

(1) one poster sharing preliminary data of a cross-sectional study measuring overall pathogen reduction on high-touch surfaces in hospital rooms pre-and-post use of the UVDI-360 Room Sanitizer as a supplement to terminal cleaning. Preliminary findings conclude 83% of sites sampled had 0 CFU following the use of the UVDI-360 Room Sanitizer.

(2) a second poster sharing preliminary data of a cross-sectional study demonstrating overall pathogen reduction in operating rooms in six minutes with the UVDI-360 Room Sanitizer used in multiple protocols: with no manual cleaning, manual cleaning in-between operating room use and as a supplement to manual terminal cleaning.

(3) an oral presentation sharing research demonstrating 3-and-4-log reductions of Candida auris at 2.44 meters using the UVDI-360 Room Sanitizer.

(4) a third poster illustrating a simulation model of microbe distribution on surfaces to inform future UV-C testing.

Title: Six ultraviolet minutes for cleaner operating theatres
Track:
Health Technology Assessment
Abstract: #DJ-15

Title: Analytical approach for a better control of environmental contamination
Track:
Hospital hygiene (including AMR), healthcare-associated infections (HAI)
Abstract: #DN-18

Title: A simulation model of microbe overlapping for the correct estimation of UV-C device log-reduction
Track:
Healthcare Technology Assessment
Abstract: #DJ-14

Oral Presentation: Tuning a UV-C device to challenge new threats in the sanitization setting of healthcare facilities
Date and Time:
October 13th, 12:15-13:15

Poster abstracts are accessible via the World Congress website, https://wcph2020.com/. The poster presentations may be accessed through UVDI’s website following their presentation.

About UVDI

UVDI’s Mission is to make a cleaner, safer, and healthier world through advanced UV-C solutions that disinfect the air and surfaces in the environments we live, work, and play in. Founded in 1949 by Louis Veloz, UVDI designs and makes next-generation germicidal Ultraviolet light solutions in California applying over 70 years and three generations of family craftsmanship and care. The UVDI-360 Room Sanitizer is now used globally in over 25 countries in the world’s leading hospitals, where it has been proven in peer-reviewed, published studies to reduce Healthcare-Associated Infections and inactivate the highest-risk pathogens. UVDI is proud to be a certified Minority

Breast Biopsy Device Market| Growing Prevalence of Breast Cancer Cases to Boost the Market Growth

The global breast biopsy device market size is poised to grow by USD 504.94 million during 2020-2024, progressing at a CAGR of about 10% throughout the forecast period, according to the latest report by Technavio. The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment. The report also provides the market impact and new opportunities created due to the COVID-19 pandemic. Download a Free Sample of REPORT with COVID-19 Crisis and Recovery Analysis.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201008005108/en/

Technavio has announced its latest market research report titled Global Breast Biopsy Devices Market 2020-2024 (Graphic: Business Wire)

The rising incidence rate of breast cancer has been providing significant business growth opportunities to market vendors. Prominent vendors in the market are focusing on expanding their product portfolios and obtaining approvals for their offerings. They have been leveraging various platforms such as conferences to gain exposure and increase awareness about breast cancer. Furthermore, various governments and private organizations are providing funding and grants to vendors to create innovative products with technologically advanced solutions to detect breast cancer at early stages. These factors will significantly contribute to the market growth over the forecast period.

Register for a free trial today and gain instant access to 17,000+ market research reports.
Technavio’s SUBSCRIPTION platform

Report Highlights:

  • The major breast biopsy device market growth came from the biopsy needles and systems segment. Breast biopsy needles are primarily used for collecting breast tissue from the suspicious areas of the breast during a breast biopsy. Needle biopsies are majorly performed as minimally invasive biopsy procedures for a better assessment of breast cancer in an outpatient setting. The need for highly skilled operators to handle imaging modalities and the reduced technical complexities of this method are driving the demand for breast biopsy needles for the extraction of normal tissues for biopsy.

  • North America was the largest breast biopsy devices market in 2019, and the region will offer several growth opportunities to market vendors during the forecast period. High technology adoption among the healthcare sector, increasing healthcare expenditure, the prevalence of breast cancer, and awareness among patients about mammograms that helps to identify breast cancer incidence will significantly drive breast biopsy devices market growth in this region over the forecast period.

  • The global breast biopsy device market is concentrated. Argon Medical Devices Inc., Becton, Dickinson and Co., Carestream Health Inc., Danaher Corp., FUJIFILM Holdings Corp., General Electric Co., Hologic Inc., Planmed Oy, Scion Medical Technologies LLC, and Siemens Healthineers AG are some of the major market participants. To help clients improve their market position, this breast biopsy device market forecast report provides a detailed analysis of the market leaders.

  • As the business impact of COVID-19 spreads, the breast biopsy device market 2020-2024 is expected to have Positive and Superior growth. As the pandemic spreads in some regions and plateaus in other regions, we reevaluate the impact on businesses and update our report forecasts.

Read the

The Medical Device Innovation Consortium (MDIC) Announces Case for Quality Collaborative Community with FDA Participation

The Medical Device Innovation Consortium (MDIC) announced today that the U.S. Food and Drug Administration’s (FDA) Center for Devices and Radiological Health (CDRH) will participate in its Case for Quality Collaborative Community (CfQcc) initiative.

The CDRH identified participation in collaborative communities as a strategic priority for 2018 to 2020. The purpose of a collaborative community is to bring together medical device stakeholders in a continuing forum of private- and public-sector members, including the FDA, to achieve common outcomes, solve shared challenges, and leverage collective opportunities. Ultimately, collaborative communities seek to contribute to the improvement of areas affecting U.S. patients and healthcare.

“The FDA is committed to working with diverse stakeholders to help ensure that patients and health care providers have access to safe, effective, and high-quality medical devices,” said Francisco Vicenty, CfQcc program manager within FDA’s CDRH. “Today’s announcement reflects the agency’s commitment to collaborative communities and builds upon existing efforts to help advance medical device quality and safety to achieve better patient outcomes. We continue to believe that collaborative communities can contribute to improvements in areas affecting patients and health care in the United States.”

The mission of the CfQcc is to convene a collaborative community of diverse stakeholders representing and serving the medical device industry with the goal of transitioning from baseline regulatory compliance to sustained, predictive practices that advance medical device quality and safety to achieve better patient outcomes. As the Convener of the CfQcc, MDIC will facilitate a neutral environment of trust and transparency, wherein a diverse group of stakeholders representing the breadth of the medical device ecosystem can collaborate openly with candor irrespective of whether they are a manufacturer, provider, patient, payor, or a member of MDIC. This initiative builds on the progress of MDIC’s Case for Quality program.

“We founded the vision and mission of the Case for Quality to reduce the risk to patients. The transformation of Case for Quality from an ecosystem program to a collaborative community really is an exciting time for us,” said Joe Sapiente, Vice President of Quality Assurance and Regulatory Affairs, Surgical, Breast, Skeletal Health, for Hologic Inc. and Chair of MDIC’s Case for Quality Steering Committee. “The formation of the Case for Quality Collaborative Community is a model for long-term success and benefit, in terms of governance, agency and industry involvement, and relationship management of our diverse stakeholders.”

In 2019, MDIC’s National Evaluation System for health Technologies Coordinating Center (NESTcc) Collaborative Community was named one of the first collaborative communities with FDA participation.

About the Medical Device Innovation Consortium
Founded in 2012, the Medical Device Innovation Consortium (MDIC) is the first public-private partnership created with the sole objective of advancing medical device regulatory science throughout the total product life cycle. MDIC’s mission is to promote public health through science and technology and to enhance trust and confidence among stakeholders. MDIC works in the pre-competitive space to facilitate the development of methods, tools, and approaches that enhance understanding and improve evaluation of product safety, quality, and

The Medical Device Innovation Consortium (MDIC) Announces New Vice President of Health Economics and Patient Value

The Medical Device Innovation Consortium (MDIC) announced today that Jo Carol Hiatt, MD, MBA, has joined the organization as Vice President of Health Economics and Patient Value (HEPV). In this role, Dr. Hiatt will facilitate efforts among the Consortium, CMS, private payers and patient advocacy groups to empower medical device companies to better understand the evidence they will need to support efficient CMS review, with the ultimate aim of increasing patient access to innovative medical devices and reducing the cost associated with commercializing these technologies. She joins MDIC following her most recent tenure leading teams to review new technologies to inform evidence-based clinical technology options for Kaiser Permanente, one of America’s leading health care providers and nonprofit health plans. She is a general surgeon and partner emeritus with the Southern California Permanente Medical Group (SCPMG).

“We are looking forward to having Jo Carol join the MDIC team,” said Pamela Goldberg, President and CEO of MDIC. “Not only does she have expertise in how technology adoption decisions are made from the payor perspective, but she also has clinical experience helping patients navigate decision-making processes about their treatment options.”

Dr. Hiatt brings 30+ years of experience working both directly with patients and from the administrative perspective to improve their access to innovative medical care. She has worked closely with FDA, researchers, clinicians, policymakers, and other stakeholders to review and assess health technologies for both public and private coverage. She was a member of the FDA Payor Communication Task Force, former chair of the EXCITE International Payor Advisory Committee, and held advisory roles on various other boards and committees. She served on the Medicare Evidence Development and Coverage Advisory Committee (MEDCAC) advising the Administrator of the Centers for Medicare & Medicaid Services (CMS) concerning the adequacy of scientific evidence available to CMS for “reasonable and necessary” determinations under Medicare.

“I am very excited to accept this opportunity supporting MDIC’s efforts accelerating patient access to technologies shown to improve clinical outcomes. I look forward to joining the team,” said Hiatt.

About the Medical Device Innovation Consortium

Founded in 2012, the Medical Device Innovation Consortium (MDIC) is the first public-private partnership created with the sole objective of advancing medical device regulatory science throughout the total product life cycle. MDIC’s mission is to promote public health through science and technology and to enhance trust and confidence among stakeholders. MDIC works in the pre-competitive space to facilitate the development of methods, tools, and approaches that enhance understanding and improve evaluation of product safety, quality, and effectiveness. Its initiatives aim to improve product safety and patient access to cutting-edge medical technology while reducing cost and time to market. For more information, visit http://www.mdic.org.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201001005183/en/

Contacts

Taylor Jackson
[email protected]
+1 202.510.9391

Source Article

KA Imaging’s Portable Dual-energy X-ray Receives Canadian Medical Device Licence from Health Canada

Canadian market comprises more than 1,000 hospitals. Number of medical and diagnostic laboratories (which include x-ray) surpasses 3,000.

A Canadian Medical Device Licence was issued September 24 by Health Canada for Reveal 35C™, created by KA Imaging – a University of Waterloo spin-off company.

Reveal is a portable dual-energy X-ray detector that enables bone and soft-tissue differentiation without motion artifacts in a single X-ray exposure. The detector simultaneously delivers DR, bone, and tissue images in one shot. Reveal can be taken to the bedside of vulnerable patients in hospital and used easily to aid emergency procedures. It is also affordable and comes at a quarter of the price of many fixed dual-energy systems.

“Getting this Health Canada licence is a major step forward for KA Imaging, especially coupled with the recent FDA clearance. As a Canadian company we are thrilled to have received Health Canada’s approval and eagerly anticipate providing our solution to the Canadian market for advance in the field of X-ray,” said Amol Karnick, President and CEO of KA Imaging.

Statistics from the Industry Canada database from 2019 show that there are more than 1,000 hospitals (including general and specialized facilities) in the country, and more than 3,000 medical and diagnostic laboratories – including X-ray services. In addition, because the detector is portable – it is the only portable dual-energy solution on the market – less obvious sectors can also benefit from the technology.

“At long-term care facilities, which care for vulnerable populations that can suffer from mobility limitations or health concerns, taking the detector to the patient can be very beneficial,” said Dr. Karim S. Karim, CTO of KA Imaging.

Reveal is already being used in clinical trials with promising results. The detector is being tested on patients suspected of having lung cancer at Grand River Hospital in Kitchener, and for detection of pneumonia (including COVID-19) in a Toronto-based hospital.

“Early triaging is an essential countermeasure to prevent the spread of COVID-19 infection, and we are confident that our technology can make a significant contribution,” said Karim.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200930005044/en/

Contacts

Fernanda Fraga
[email protected]
226 215 9897

Source Article